drugset
drugset / Trial / NCT00187161

Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL

NCT00187161 ↗

Phase 2 Completed 68 enrolled St. Jude Children's Research Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell acute lymphoblastic leukemia can be delivered in this setting with acceptable toxicity.

Timeline

Start
1994-11
Primary completion
—
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 1000 mg/m2 Intravenous
Subject Cytarabine Small molecule 6 mg Intravenous
Subject Cytarabine Small molecule 15 mg Intravenous
Subject Cytarabine Small molecule 20 mg Intravenous
Subject Cytarabine Small molecule 25 mg Intravenous
Subject Cytarabine Small molecule 30 mg Intravenous
Subject Cytarabine Small molecule 50 mg/m2 Intravenous
Subject Cytarabine Small molecule 100 mg/m2 Intravenous
Subject Cytarabine Small molecule 3000 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 60 mg/m2 Intravenous
Subject Etoposide Small molecule 150 mg/m2 Intravenous
Subject Etoposide Small molecule 200 mg/m2 Intravenous
Subject Methotrexate Small molecule 6 mg Intravenous
Subject Methotrexate Small molecule 8 mg Intravenous
Subject Methotrexate Small molecule 10 mg Intravenous
Subject Methotrexate Small molecule 12 mg Intravenous
Subject Methotrexate Small molecule 15 mg Intravenous
Subject Methotrexate Small molecule 3000 mg/m2 Intravenous
Subject Methotrexate Small molecule 8000 mg/m2 Intravenous
Subject Prednisone Other / unclassified 60 mg/m2 Oral
Subject Vincristine Small molecule 1 mg/m2 Intravenous
Subject Vincristine Small molecule 2 mg/m2 Intravenous

Indications

B-cell acute lymphoblastic leukemia